Hemolytic anemia in COVID-19.
Ann Hematol
; 101(9): 1887-1895, 2022 Sep.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2248675
ABSTRACT
COVID-19 is a global pandemic triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 entry point involves the interaction with angiotensin-converting enzyme 2 (ACE2) receptor, CD147, and erythrocyte Band3 protein. Hemolytic anemia has been linked to COVID-19 through induction of autoimmune hemolytic anemia (AIHA) caused by the formation of autoantibodies (auto-Abs) or directly through CD147 or erythrocyte Band3 protein-mediated erythrocyte injury. Here, we aim to provide a comprehensive view of the potential mechanisms contributing to hemolytic anemia during the SARS-CoV-2 infection. Taken together, data discussed here highlight that SARS-CoV-2 infection may lead to hemolytic anemia directly through cytopathic injury or indirectly through induction of auto-Abs. Thus, as SARS-CoV-2-induced hemolytic anemia is increasingly associated with COVID-19, early detection and management of this condition may prevent the poor prognostic outcomes in COVID-19 patients. Moreover, since hemolytic exacerbations may occur upon medicines for COVID-19 treatment and anti-SARS-CoV-2 vaccination, continued monitoring for complications is also required. Given that, intelligent nanosystems offer tools for broad-spectrum testing and early diagnosis of the infection, even at point-of-care sites.
Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
COVID-19
/
/
Anémie hémolytique
Type d'étude:
Étude pronostique
Les sujets:
Covid long
/
Vaccins
Limites du sujet:
Humains
langue:
Anglais
Revue:
Ann Hematol
Thème du journal:
Hématologie
Année:
2022
Type de document:
Article
Pays d'affiliation:
S00277-022-04907-7
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS